基于人群的计算机断层扫描肺癌筛查情景的性能与成本效果:加拿大安大略省的微观模拟建模分析
该研究采用微观模拟建模,从第三方医疗付费者视角评估加拿大安大略省基于人群的CT肺癌筛查成本效果。结果显示,严格吸烟资格标准(如≥40包年且当前吸烟或戒烟≤10年)的年度筛查在55-75岁人群更具成本效果,增量成本效果比为每获得生命年41136加元,低于50000加元阈值。
要点
- 年度筛查比每两年筛查更具成本效果。
- 严格吸烟资格标准(如≥40包年)比宽松标准更具成本效果,生命年获益差异不大。
- 55-75岁年度筛查(≥40包年且当前吸烟或戒烟≤10年)的增量成本效果比为每生命年41136加元。
核心结论
- 采用严格吸烟资格标准的肺癌筛查在基于人群的环境中具有成本效果。
研究设计与样本
- 研究使用微观模拟建模,数据来源包括安大略省健康保险计划、安大略省癌症登记处、吸烟行为调查和国家肺筛查试验。
- 研究对象为1940年至1969年出生的人群,从第三方医疗付费者视角在终生时间范围内进行分析。
- 从2015年开始,检查了576种CT筛查情景,这些情景在筛查开始和结束年龄、吸烟资格标准和筛查间隔上有所不同。
主要发现
- 基础案例分析表明,年度筛查比每两年筛查更具成本效果。
- 要求至少20包年的资格标准情景被要求更高累积包年数的情景所支配。
- 55-75岁年度筛查(≥40包年且当前吸烟或戒烟≤10年)与60-75岁年度筛查(≥40包年且当前吸烟或戒烟≤10年)相比,增量成本效果比为每获得生命年41136加元(2015年5月1日美元33825元)。
- 假设归因成本降低50%或升高50%,该情景的增量成本效果比分别为38240加元(2015年5月1日美元31444元)或48525加元(2015年5月1日美元39901元)。
- 假设CT检查成本降低50%或升高50%,该情景的增量成本效果比分别为28630加元(2015年5月1日美元23542元)或73507加元(2015年5月1日美元60443元)。
关键数值与推荐
- 在50000加元(2015年5月1日美元41114元)的成本效果阈值下,55-75岁年度筛查(≥40包年且当前吸烟或戒烟≤10年)被认为是成本效果最优的。
- 该情景将至少筛查总人口(曾吸烟和从不吸烟者)的9.56%(499261人)一次,需要4788523次CT检查,并使总人群肺癌死亡率降低9.05%(预防13108例肺癌死亡),同时12.53%的筛查发现癌症将被过度诊断(4282例过度诊断病例)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 分析未纳入生活质量。
- 随访程序的假设基于国家肺筛查试验的数据,可能无法推广到基于人群的环境。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The National Lung Screening Trial (NLST) results indicate that computed tomography (CT) lung cancer screening for current and former smokers with three annual screens can be cost-effective in a trial setting. However, the cost-effectiveness in a population-based setting with >3 screening rounds is uncertain. Therefore, the objective of this study was to estimate the cost-effectiveness of lung cancer screening in a population-based setting in Ontario, Canada, and evaluate the effects of screening eligibility criteria. METHODS AND FINDINGS: This study used microsimulation modeling informed by various data sources, including the Ontario Health Insurance Plan (OHIP), Ontario Cancer Registry, smoking behavior surveys, and the NLST. Persons, born between 1940 and 1969, were examined from a third-party health care payer perspective across a lifetime horizon. Starting in 2015, 576 CT screening scenarios were examined, varying by age to start and end screening, smoking eligibility criteria, and screening interval. Among the examined outcome measures were lung cancer deaths averted, life-years gained, percentage ever screened, costs (in 2015 Canadian dollars), and overdiagnosis. The results of the base-case analysis indicated that annual screening was more cost-effective than biennial screening. Scenarios with eligibility criteria that required as few as 20 pack-years were dominated by scenarios that required higher numbers of accumulated pack-years. In general, scenarios that applied stringent smoking eligibility criteria (i.e., requiring higher levels of accumulated smoking exposure) were more cost-effective than scenarios with less stringent smoking eligibility criteria, with modest differences in life-years gained. Annual screening between ages 55-75 for persons who smoked ≥40 pack-years and who currently smoke or quit ≤10 y ago yielded an incremental cost-effectiveness ratio of $41,136 Canadian dollars ($33,825 in May 1, 2015, United States dollars) per life-year gained (compared to annual screening between ages 60-75 for persons who smoked ≥40 pack-years and who currently smoke or quit ≤10 y ago), which was considered optimal at a cost-effectiveness threshold of $50,000 Canadian dollars ($41,114 May 1, 2015, US dollars). If 50% lower or higher attributable costs were assumed, the incremental cost-effectiveness ratio of this scenario was estimated to be $38,240 ($31,444 May 1, 2015, US dollars) or $48,525 ($39,901 May 1, 2015, US dollars), respectively. If 50% lower or higher costs for CT examinations were assumed, the incremental cost-effectiveness ratio of this scenario was estimated to be $28,630 ($23,542 May 1, 2015, US dollars) or $73,507 ($60,443 May 1, 2015, US dollars), respectively. This scenario would screen 9.56% (499,261 individuals) of the total population (ever- and never-smokers) at least once, which would require 4,788,523 CT examinations, and reduce lung cancer mortality in the total population by 9.05% (preventing 13,108 lung cancer deaths), while 12.53% of screen-detected cancers would be overdiagnosed (4,282 overdiagnosed cases). Sensitivity analyses indicated that the overall results were most sensitive to variations in CT examination costs. Quality of life was not incorporated in the analyses, and assumptions for follow-up procedures were based on data from the NLST, which may not be generalizable to a population-based setting. CONCLUSIONS: Lung cancer screening with stringent smoking eligibility criteria can be cost-effective in a population-based setting.
引用
- Ten Haaf K, Tammemägi MC, Bondy SJ, et al. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada. PLoS Med. 2017. PMID: 28170394. doi:10.1371/journal.pmed.1002225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。